Founded in 2019, Juncell Therapeutics has been hailed as a "unicorn company" for developing innovative TIL therapies in the field of solid tumor treatment. As a national high-tech enterprise and one of "Shanghai Specialized and Innovative Enterprises", we are currently at the stage of clinical research. In addition, we won the highest award "Excellence Award" in the "National Disruptive Technology Innovation Competition" organized by the Ministry of Science and Technology of China, and was selected as a candidate for disruptive technology in MOST's database.

      Juncell Therapeutics has established a facility platform covering 3,000㎡ including 2,000㎡ GMP production workshops and quality control laboratories, with a supporting quality management system.  In order to meet the production capacity of TIL pipelines, over 16,000㎡  commercial production is under construction in stages.  By virtue of the innovative DeepTIL^® cell expansion platform and the NovaGMP^® gene modification platform, our company has developed a series of natural TIL and non-viral vector-based genetically modified TIL therapies, among which, 2 piplines are in clinical trials.  7 patients achieved CR, among which the longest is nearly 3 years, with lower intensity pretreatment, no IL-2 infused, no SAE occurred of all patients.

      As the world's first TIL therapy without lymphodepletion or IL-2 injection, GC101 was also one of the first TIL therapies granted implied IND by NMPA in April 2022.  The phase I clinical trial centers include Chinese PLA General Hospital, Fudan University Shanghai Cancer Center, Tenth People's Hospital of Tongji University, Zhongshan Hospital Fudan University, Obstetrics & Gynecology Hospital of Fudan University, The Second Affiliated Hospital Zhejiang University School of Medicine, Shanghai Ninth People´s Hospital, BEIJING CANCER HOSPITAL, etc.. 

      Moreover, the world's first non-viral vector-based genetically modified TIL therapy also exhibited excellent safety and efficacy in patients with relapsed/refractory solid tumors.  GC203 as the world's first non-viral vector-based genetically modified TIL therapy,  is granted implied IND by NMPA in April 2024.  The leading clinical center is  Fudan University Shanghai Cancer Center.

      Currently, we have achieved B rounds of financing, and received 8 project fundings from National, Shanghai Science and Technology Commission and Shanghai Development and Reform Commission.  Moreover, 30+ Chinese invention patents and PCTs have been laid out about our core technologies.